Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2476 to 2490 of 7686 results

  1. Advanced breast cancer: diagnosis and management (Partial update)

    In development [GID-NG10430] Expected publication date: TBC

    NICE guideline
    In development

  2. Pneumonia QS update

    In development [GID-QS10190] Expected publication date: 14 August 2025

    Quality standard
    In development

  3. Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]

    Awaiting development [GID-TA11018] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Advanced breast cancer: diagnosis and management (Partial update): draft scope consultation

    We are listening to your views on this NICE guideline. Comments close 21 November 2024.

    NICE guideline
    In consultation

  5. Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6328]

    In development [GID-TA11408] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (Review of TA761) [ID5120]

    In development [GID-TA11369] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (MA review of TA760) [ID6293]

    In development [GID-TA11480] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack (DG59)

    Evidence-based recommendations on CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack

    Diagnostics guidance
    Published
    31 July 2024
    View recommendations

    Sections for DG59

  9. Adalimumab for treating early Dupuytren's contracture [ID6276]

    Awaiting development [GID-TA11363] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Polyhexanide eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]

    Awaiting development [GID-TA11643] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Lenacapavir for HIV pre-exposure prophylaxis in people 16 years and over at risk of infection [ID6495]

    Awaiting development [GID-TA11638] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome

    In development [GID-DG10074] Expected publication date: 19 December 2024

    Diagnostics guidance
    In development

  13. Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]

    In development [GID-TA10165] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Spesolimab for treating generalised pustular psoriasis flares [ID3963]

    In development [GID-TA10871] Expected publication date: 19 March 2025

    Technology appraisal guidance
    In development

  15. Pembrolizumab with platinum-based chemotherapy then pembrolizumab maintenance for treating primary advanced or recurrent endometrial cancer ID6381

    In development [GID-TA11461] Expected publication date: 16 April 2025

    Technology appraisal guidance
    In development